Viral Pathogenesis, Modulation of Immune Receptor Signaling and Treatment

  • Walter M. Kim
  • Alexander B. Sigalov
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 640)


During the co-evolution of viruses and their hosts, the latter have equipped themselves with an elaborate immune system to defend themselves from the invading viruses. In order to establish a successful infection, replicate and persist in the host, viruses have evolved numerous strategies to counter and evade host antiviral immune responses as well as exploit them for productive viral replication. These strategies include those that target immune receptor transmembrane signaling. Uncovering the exact molecular mechanisms underlying these critical points in viral pathogenesis will not only help us understand strategies used by viruses to escape from the host immune surveillance but also reveal new therapeutic targets for antiviral as well as immunomodulatory therapy. In this chapter, based on our current understanding of transmembrane signal transduction mediated by multichain immune recognition receptors (MIRRs) and the results of sequence analysis, we discuss the MIRR-targeting viral strategies of immune evasion and suggest their possible mechanisms that, in turn, reveal new points of antiviral intervention. We also show how two unrelated enveloped viruses, human immunodeficiency virus and human cytomegalovirus, use a similar mechanism to modulate the host immune response mediated by two functionally different MIRRs—T-cell antigen receptor and natural killer cell receptor, NKp30. This suggests that it is very likely that similar general mechanisms can be or are used by other viral and possibly nonviral pathogens.


Human Immunodeficiency Virus Simian Immunodeficiency Virus Viral Pathogenesis Severe Acute Respiratory Syndrome Coronavirus Viral Strategy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449:819–826.PubMedCrossRefGoogle Scholar
  2. 2.
    Pichlmair A, Reis e Sousa C. Innate recognition of viruses. Immunity 2007; 27:370–383.PubMedCrossRefGoogle Scholar
  3. 3.
    Takeuchi O, Akira S. Recognition of viruses by innate immunity. Immunol Rev 2007; 220:214–224.PubMedCrossRefGoogle Scholar
  4. 4.
    Schroder M, Bowie AG. An arms race: Innate antiviral responses and counteracting viral strategies. Biochem Soc Trans 2007; 35:1512–1514.PubMedCrossRefGoogle Scholar
  5. 5.
    Loo YM, Gale M Jr. Viral regulation and evasion of the host response. Curr Top Microbiol Immunol 2007; 316:295–313.PubMedCrossRefGoogle Scholar
  6. 6.
    Keller BC, Johnson CL, Erickson AK et al. Innate immune evasion by hepatitis C virus and West Nile virus. Cytokine Growth Factor Rev 2007; 18:535–544.PubMedCrossRefGoogle Scholar
  7. 7.
    Coscoy L. Immune evasion by Kaposi’s sarcoma-associated herpesvirus. Nat Rev Immunol 2007; 7:391–401.PubMedCrossRefGoogle Scholar
  8. 8.
    Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell Microbiol 2006; 8:907–922.PubMedCrossRefGoogle Scholar
  9. 9.
    van Wamel WJ, Rooijakkers SH, Ruyken M et al. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of staphylococcus aureus are located on beta-hemolysin-converting bacteriophages. J Bacteriol 2006; 188:1310–1315.PubMedCrossRefGoogle Scholar
  10. 10.
    Rajagopalan S, Long EO. Viral evasion of NK-cell activation. Trends Immunol 2005; 26:403–405.PubMedCrossRefGoogle Scholar
  11. 11.
    Kosugi I, Kawasaki H, Arai Y et al. Innate immune responses to cytomegalovirus infection in the developing mouse brain and their evasion by virus-infected neurons. Am J Pathol 2002; 161:919–928.PubMedGoogle Scholar
  12. 12.
    Haller O, Weber F. Pathogenic viruses: Smart manipulators of the interferon system. Curr Top Microbiol Immunol 2007; 316:315–334.PubMedCrossRefGoogle Scholar
  13. 13.
    Saito T, Gale M Jr. Principles of intracellular viral recognition. Curr Opin Immunol 2007; 19:17–23.PubMedCrossRefGoogle Scholar
  14. 14.
    Kurt-Jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immimol 2000; 1:398–401.CrossRefGoogle Scholar
  15. 15.
    Pasare C, Medzhitov R. Toll-like receptors: Linking innate and adaptive immunity. Adv Exp Med Biol 2005; 560:11–18.PubMedCrossRefGoogle Scholar
  16. 16.
    Jancway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54(Pt 1):1–13.Google Scholar
  17. 17.
    Doly J, Civas A, Navarro S et al. Type I interferons: Expression and signalization. Cell Mol Life Sci 1998; 54:1109–1121.PubMedCrossRefGoogle Scholar
  18. 18.
    Kunzi MS, Pitha PM. Interferon targeted genes in host defense. Autoimmunity 2003; 36:457–461.PubMedCrossRefGoogle Scholar
  19. 19.
    Le Page C, Genin P, Baines MG et al. Interferon activation and innate immunity. Rev Immunogenet 2000; 2:374–386.PubMedGoogle Scholar
  20. 20.
    Ozato K, Tailor P, Kubota T. The interferon regulatory factor family in host defense: Mechanism of action. J Biol Chem 2007; 282:20065–20069.PubMedCrossRefGoogle Scholar
  21. 21.
    Galligan CL, Murooka TT, Rahbar R et al. Interferons and viruses: signaling for supremacy. Immunol Res 2006; 35:27–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Perry AK, Chen G, Zheng D et al. The host type I interferon response to viral and bacterial infections. Cell Res 2005; 15:407–422.PubMedCrossRefGoogle Scholar
  23. 23.
    Bonjardim CA. Interferons (IFNs) are key cytokines in both innate and adaptive antiviral immune responses—and viruses counteract IFN action. Microbes Infect 2005; 7:569–578.PubMedCrossRefGoogle Scholar
  24. 24.
    Cebulla CM, Miller DM, Sedmak DD. Viral inhibition of interferon signal transduction. Intervirology 1999; 42:325–330.PubMedCrossRefGoogle Scholar
  25. 25.
    Garcia-Sastre A. Mechanisms of inhibition of the host interferon alpha/beta-mediated antiviral responses by viruses. Microbes Infect 2002; 4:647–655.PubMedCrossRefGoogle Scholar
  26. 26.
    Goodbourn S, Didcock L, Randall RE. Interferons: Cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000; 81:2341–2364.PubMedGoogle Scholar
  27. 27.
    Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev 2001; 12:143–156.PubMedCrossRefGoogle Scholar
  28. 28.
    Yang I, Kremen TJ, Giovannone AJ et al. Modulation of major histocompatibility complex Class I molecules and major histocompatibility complex-boimd immunogenic peptides induced by interferon-alpha and interferon-gamma treatment of human glioblastoma multiforme. J Neurosurg 2004; 100:310–319.PubMedGoogle Scholar
  29. 29.
    Agrawal S, Kishore MC. MHC class I gene expression and regulation. J Hematother Stem Cell Res 2000; 9:795–812.PubMedCrossRefGoogle Scholar
  30. 30.
    Thomas HE, Parker JL, Schreiber RD et al. IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. J Clin Invest 1998; 102:1249–1257.PubMedCrossRefGoogle Scholar
  31. 31.
    Gruschwitz MS, Vieth G. Up-regulation of class II major histocompatibility complex and intercellular adhesion molecule 1 expression on scleroderma fibroblasts and endothelial cells by interferon-gamma and tumor necrosis factor alpha in the early disease stage. Arthritis Rheum 1997; 40:540–550.PubMedCrossRefGoogle Scholar
  32. 32.
    Dhib-Jalbut SS, Xia Q, Drew PD et al. Differential up-regulation of HLA class I molecules on neuronal and glial cell lines by virus infection correlates with differential induction of IFN-beta. J Immunol 1995; 155:2096–2108.PubMedGoogle Scholar
  33. 33.
    Chang CH, Hammer J, Loh JE et al. The activation of major histocompatibility complex class I genes by interferon regulatory factor-1 (IRF-1). Immunogenetics 1992; 35:378–384.PubMedCrossRefGoogle Scholar
  34. 34.
    Beniers AJ, Peelen WP, Debruyne FM et al. HLA-class-I and-class-II expression on renal tirnior xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF. Int J Cancer 1991; 48:709–716.PubMedCrossRefGoogle Scholar
  35. 35.
    Giacomini P, Fisher PB, Duigou GJ et al. Regulation of class II MHC gene expression by interferons: insights into the mechanism of action of interferon (review). Anticancer Res 1988; 8:1153–1161.PubMedGoogle Scholar
  36. 36.
    Sigalov AB. Immune cell signaling: A novel mechanistic model reveals new therapeutic targets. Trends Pharmacol Sci 2006; 27:518–524.PubMedCrossRefGoogle Scholar
  37. 37.
    Lwoff A, Tournier P. The classification of viruses. Annu Rev Microbiol 1966; 20:45–74.PubMedCrossRefGoogle Scholar
  38. 38.
    Lwoff A, Home R, Tournier P. A system of viruses. Cold Spring Harb Symp Quant Biol 1962; 27:51–55.PubMedGoogle Scholar
  39. 39.
    Baltimore D. Expression of animal virus genomes. Bacteriol Rev 1971; 35:235–241.PubMedGoogle Scholar
  40. 40.
    Sigalov AB. Interaction between HIV gp4l fusion peptide and T-cell receptor: Putting the puzzle pieces back together. FASEB J 2007; 21:1633–1634; author reply 1635.PubMedCrossRefGoogle Scholar
  41. 41.
    Sigalov AB. Transmembrane interactions as immunotherapeutic targets: Lessons from viral pathogenesis. Adv Exp Med Biol 2007; 601:335–344.PubMedGoogle Scholar
  42. 42.
    Vlasak R, Luytjes W, Spaan W et al. Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. Proc Natl Acad Sci USA 1988; 85:4526–4529.PubMedCrossRefGoogle Scholar
  43. 43.
    Higa HH, Rogers GN, Paulson JC. Influenza virus hemagglutinins differentiate between receptor determinants bearing N-acetyl-, N-glycollyl-and N,O-diacetylneuraminic acids. Virology 1985; 144:279–282.PubMedCrossRefGoogle Scholar
  44. 44.
    Weis W, Brown JH, Cusack S et al. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 1988; 333:426–431.PubMedCrossRefGoogle Scholar
  45. 45.
    Gentsch JR, Pacitti AF. Differential interaction of reovirus type 3 with sialylated receptor components on animal cells. Virology 1987; 161:245–248.PubMedCrossRefGoogle Scholar
  46. 46.
    Paul RW, Choi AH, Lee PW. The alpha-anomeric form of sialic acid is the minimal receptor determinant recognized by reovirus. Virology 1989; 172:382–385.PubMedCrossRefGoogle Scholar
  47. 47.
    Paul RW, Lee PW. Glycophorin is the reovirus receptor on human erythrocytes. Virology 1987; 159:94–101.PubMedCrossRefGoogle Scholar
  48. 48.
    Greve JM, Davis G, Meyer AM et al. The major human rhinovirus receptor is ICAM-1. Cell 1989; 56:839–847.PubMedCrossRefGoogle Scholar
  49. 49.
    Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: Molecular cloning, nucleotide sequence and expression of a new member of the immunoglobulin superfamily. Cell 1989; 56:855–865.PubMedCrossRefGoogle Scholar
  50. 50.
    Staunton DE, Merluzzi VJ, Rothlein R et al. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell 1989; 56:849–853.PubMedCrossRefGoogle Scholar
  51. 51.
    Tomassini JE, Graham D, DeWitt CM et al. cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1989; 86:4907–4911.PubMedCrossRefGoogle Scholar
  52. 52.
    Dalgleish AG, Beverley PC, Clapham PR et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312:763–767.PubMedCrossRefGoogle Scholar
  53. 53.
    Klatzmann D, Champagne E, Chamaret S et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984; 312:767–768.PubMedCrossRefGoogle Scholar
  54. 54.
    Maddon PJ, Dalgleish AG, McDougal JS et al. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47:333–348.PubMedCrossRefGoogle Scholar
  55. 55.
    McDougal JS, Kennedy MS, Sligh JM et al. Binding of HTLV-III/LAV to T4+ T-cells by a complex of the 110K viral protein and the T4 molecule. Science 1986; 231:382–385.PubMedCrossRefGoogle Scholar
  56. 56.
    Sattentau QJ, Weiss RA. The CD4 antigen: Physiological ligand and HIV receptor. Cell 1988; 52:631–633.PubMedCrossRefGoogle Scholar
  57. 57.
    White JM. Membrane fusion. Science 1992; 258:917–924.PubMedCrossRefGoogle Scholar
  58. 58.
    White JM. Viral and cellular membrane fusion proteins. Annu Rev Physiol 1990; 52:675–697.PubMedCrossRefGoogle Scholar
  59. 59.
    Daniels PS, Jeffries S, Yates P et al. TKe receptor-binding and membrane-fusion properties of influenza virus variants selected using anti-haemagglutinin monoclonal antibodies. EMBO J 1987; 6:1459–1465.PubMedGoogle Scholar
  60. 60.
    Hoekstra D, Kok JW. Entry mechanisms of enveloped viruses. Implications for fusion of intracellular membranes. Biosci Rep 1989; 9:273–305.PubMedCrossRefGoogle Scholar
  61. 61.
    Lamb RA. Paramyxovirus fusion: A hypothesis for changes. Virology 1993; 197:1–11.PubMedCrossRefGoogle Scholar
  62. 62.
    Marsh M, Helenius A. Virus entry into animal cells. Adv Virus Res 1989; 36:107–151.PubMedCrossRefGoogle Scholar
  63. 63.
    Underwood PA, Skehel JJ, Wiley DC. Receptor-binding characteristics of monoclonal antibody-selected antigenic variants of influenza virus. J Virol 1987; 61:206–208.PubMedGoogle Scholar
  64. 64.
    Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem 1987; 56:365–394.PubMedCrossRefGoogle Scholar
  65. 65.
    Tyler KLaF, Bernard N. Fundamental Virology. 3rd ed. Philadelphia: Lippincott—Raven Publishers, 1996:161–206.Google Scholar
  66. 66.
    Center RJ, Leapman RD, Lebowitz J et al. Oligomcric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol 2002; 76:7863–7867.PubMedCrossRefGoogle Scholar
  67. 67.
    Weiss CD, Levy JA, White JM. Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol 1990; 64:5674–5677.PubMedGoogle Scholar
  68. 68.
    Zhang CW, Chishti Y, Hussey RE et al. Expression, purification and characterization of recombinant HIV gpl40. The gp41 ectodomain of HIV or simian immunodeficiency virus is sufiicient to maintain the retroviral envelope glycoprotein as a trimcr. J Biol Chem 2001; 276:39577–39585.PubMedCrossRefGoogle Scholar
  69. 69.
    Alkhatib G, Combadiere C, Broder CC et al. CC CKR5: A RANTES, MlP-lalpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955–1958.PubMedCrossRefGoogle Scholar
  70. 70.
    Choe H, Farzan M, Sun Y et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85:1135–1148.PubMedCrossRefGoogle Scholar
  71. 71.
    Deng H, Liu R, Ellmeier W et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996; 381:661–666.PubMedCrossRefGoogle Scholar
  72. 72.
    Doranz BJ, Ruckcr J, Yi Y et al. A dual-tropic primary HIV-l isolate that uses fiisin and the beta-chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. Cell 1996; 85:1149–1158.PubMedCrossRefGoogle Scholar
  73. 73.
    Feng Y, Broder CC, Kennedy PE et al. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272:872–877.PubMedCrossRefGoogle Scholar
  74. 74.
    Trkola A, Dragic T, Arthos J et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its coreceptor CCR-5. Nature 1996; 384:184–187.PubMedCrossRefGoogle Scholar
  75. 75.
    Wu L, Gerard NP, Wyatt R et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384:179–183.PubMedCrossRefGoogle Scholar
  76. 76.
    Quintana FJ, Gerber D, Kent SC et al. HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T-cell activation. J Clin Invest 2005; 115:2149–2158.PubMedCrossRefGoogle Scholar
  77. 77.
    Call ME, Pyrdol J, Wiedmann M et al. The organizing principle in the formation of the T-cell recep-tor-CD3 complex. Cell 2002; 111:967–979.PubMedCrossRefGoogle Scholar
  78. 78.
    Sigalov A. Multi-chain immune recognition receptors: Spatial organization and signal transduction. Semin Immunol 2005; 17:51–64.PubMedCrossRefGoogle Scholar
  79. 79.
    Sigalov AB. Multichain immune recognition receptor signaling: Different players, same game? Trends Immunol 2004; 25:583–589.PubMedCrossRefGoogle Scholar
  80. 80.
    Quintana FJ, Gerber D, Bloch I et al. A structurally altered D,L-amino acid TCRalpha transmembrane peptide interacts with the TCRalpha and inhibits T-cell activation in vitro and in an animal model. Biochemistry 2007; 46:2317–2325.PubMedCrossRefGoogle Scholar
  81. 81.
    Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science 1988; 242:1168–1171.PubMedCrossRefGoogle Scholar
  82. 82.
    DeMeritt IB, Milford LE, Yurochko AD. Activation of the NF-kappaB pathway in human cytomeg-alovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter. J Virol 2004; 78:4498–4507.CrossRefGoogle Scholar
  83. 83.
    Mocarski E Jr, Hahn G, White KL et al. Myeloid cell recruitment and function in pathogenesis and latency. In: Reddehase M, ed. Cytomegaloviruses: Pathogenesis, Molecular Biology and Infection Control. Norfolk: Caister Scientific Press, 2006:465–482.Google Scholar
  84. 84.
    Mocarski E, Shenk T, Pass RF. Cytomegaloviruses. In: Knipe D, Howley PM, eds. Fields Virology. Philadelphia: Lippincott Williams and Wilkins, 2007; 2:2702–2772.Google Scholar
  85. 85.
    Browne EP, Shenk T. Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proc Natl Acad Sci USA 2003; 100:11439–11444.PubMedCrossRefGoogle Scholar
  86. 86.
    Paulus C, Krauss S, Nevels M. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc Natl Acad Sci USA 2006; 103:3840–3845.PubMedCrossRefGoogle Scholar
  87. 87.
    Wiertz E, Hill A, Tortorella D et al. Cytomegaloviruses use multiple mechanisms to elude the host immune response. Immunol Lett 1997; 57:213–216.PubMedCrossRefGoogle Scholar
  88. 88.
    Arnon TI, Achdout H, Levi O et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immimol 2005; 6:515–523.CrossRefGoogle Scholar
  89. 89.
    Jones KS, Fugo K, Petrow-Sadowski C et al. Human T-cell leukemia vims type 1 (HTLV-1) and HTLV-2 use different receptor complexes to enter T-cells. J Virol 2006; 80:8291–8302.PubMedCrossRefGoogle Scholar
  90. 90.
    Manel N, Taylor N, Kinet S et al. HTLV envelopes and their receptor GLUTl, the ubiquitous glucose transporter: a new vision on HTLV infection? Front Biosci 2004; 9:3218–3241.PubMedCrossRefGoogle Scholar
  91. 91.
    Manel N, Kim FJ, Kinet S et al. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003; 115:449–459.PubMedCrossRefGoogle Scholar
  92. 92.
    Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007; 7:365–378.PubMedCrossRefGoogle Scholar
  93. 93.
    Pinon JD, Kelly SM, Price NC et al. An antiviral peptide targets a coiled-coil domain of the human T-cell leukemia virus envelope glycoprotein. J Virol 2003; 77:3281–3290.PubMedCrossRefGoogle Scholar
  94. 94.
    Andersen PS, Geisler C, Buus S et al. Role of the T-cell receptor ligand affinity in T-cell activation by bacterial superantigens. J Biol Chem 2001; 276:33452–33457.PubMedCrossRefGoogle Scholar
  95. 95.
    Igakura T, Stinchcombe JC, Goon PK et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 2003; 299:1713–1716.PubMedCrossRefGoogle Scholar
  96. 96.
    Daenke S, Booth S. HTLV-1-induced cell fusion is limited at two distinct steps in the fusion pathway after receptor binding. J Cell Sci 2000; 113(Pt l):37–44.PubMedGoogle Scholar
  97. 97.
    Jones PL, Korte T, Blumenthal R. Conformational changes in cell surface HIV-1 envelope glyco-proteins are triggered by cooperation between cell surface CD4 and coreceptors. J Biol Chem 1998; 273:404–409.PubMedCrossRefGoogle Scholar
  98. 98.
    Wilson KA, Bar S, Maerz AL et al. The conserved glycine-rich segment linking the N-terminal fusion peptide to the coiled coil of human T-cell leukemia virus type 1 transmembrane glycoprotein gp21 is a determinant of membrane fusion function. J Virol 2005; 79:4533–4539.PubMedCrossRefGoogle Scholar
  99. 99.
    Wilson KA, Maerz AL, Poumbourios P. Evidence that the transmembrane domain proximal region of the human T-cell leukemia virus type 1 fusion glycoprotein gp21 has distinct roles in the prefiision and fusion-activated states. J Biol Chem 2001; 276:49466–49475.PubMedCrossRefGoogle Scholar
  100. 100.
    Cianciolo GJ, Copeland TD, Oroszlan S et al. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 1985; 230:453–455.PubMedCrossRefGoogle Scholar
  101. 101.
    Ruegg CL, Monell CR, Strand M. Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1. J Virol 1989; 63:3257–3260.PubMedGoogle Scholar
  102. 102.
    Yaddanapudi K, Palacios G, Towner JS et al. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of Ebola and Marburg viruses. FASEB J 2006; 20:2519–2530.PubMedCrossRefGoogle Scholar
  103. 103.
    Bukrinsky MI, Sharova N, McDonald TL et al. Association of integrase, matrix and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci USA 1993; 90:6125–6129.PubMedCrossRefGoogle Scholar
  104. 104.
    Farnet CM, Haseltine WA. Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. J Virol 1991; 65:1910–1915.PubMedGoogle Scholar
  105. 105.
    Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 1997; 71:5382–5390.PubMedGoogle Scholar
  106. 106.
    Turlure F, Devroe E, Silver PA et al. Human cell proteins and human immunodeficiency virus DNA integration. Front Biosci 2004; 9:3187–3208.PubMedCrossRefGoogle Scholar
  107. 107.
    Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995; 69:5087–5094.PubMedGoogle Scholar
  108. 108.
    Freed EaM, MA. HIVs and their replication. In: Knipe DaH, PM, eds. Fields Virology. 5 ed. Philadel-phia: Lippincott Williams and Wilkins, 2007; 1:2107–2185.Google Scholar
  109. 109.
    Gibellini D, Vitone F, Schiavone P et al. HIV-1 tat protein and cell proliferation and survival: A brief review. New Microbiol 2005; 28:95–109.PubMedGoogle Scholar
  110. 110.
    Amarapal P, Tantivanich S, Balachandra K et al. The role of the Tat gene in the pathogenesis of HIV infection. Southeast Asian J Trop Med Public Health 2005; 36:352–361.PubMedGoogle Scholar
  111. 111.
    Seelamgari A, Maddukuri A, Berro R et al. Role of viral regulatory and accessory proteins in HIV-1 replication. Front Biosci 2004; 9:2388–2413.PubMedCrossRefGoogle Scholar
  112. 112.
    Strebel K. Virus-host interactions: Role of HIV proteins Vif, Tat and Rev. AIDS 2003; 17(Suppl 4):S25–34.Google Scholar
  113. 113.
    Keppler OT, Tibroni N, Venzke S et al. Modulation of specific surface receptors and activation sensi-tization in primary resting CD4+ T-lymphocytes by the Nef protein of HIV-1. J Leukoc Biol 2006; 79:616–627.PubMedCrossRefGoogle Scholar
  114. 114.
    Schrager JA, Marsh JW. HIV-1 Nef increases T-cell activation in a stimulus-dependent manner. Proc Nad Acad Sci USA 1999; 96:8167–8172.CrossRefGoogle Scholar
  115. 115.
    Simmons A, Aluvihare V, McMichael A. Nef triggers a transcriptional program in T-cells imitating single-signal T-cell activation and inducing HIV virulence mediators. Immunity 2001; 14:763–777.PubMedCrossRefGoogle Scholar
  116. 116.
    Baur AS, Sawai ET, Dazin P et al. HIV-1 Nef leads to inhibition or activation of T-cells depending on its intracellular localization. Immunity 1994; 1:373–384.PubMedCrossRefGoogle Scholar
  117. 117.
    Djordjevic JT, Schibeci SD, Stewart GJ et al. HIV type 1 Nef increases the association of T-cell receptor (TCR)-signaling molecules with T-cell rafts and promotes activation-induced raft fusion. AIDS Res Hum Retroviruses 2004; 20:547–555.PubMedCrossRefGoogle Scholar
  118. 118.
    Ahmad N, Venkatesan S. Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. Science 1988; 241:1481–1485.PubMedCrossRefGoogle Scholar
  119. 119.
    Garcia JV, Miller AD. Downregulation of cell surface CD4 by nef. Res Virol 1992; 143:52–55.PubMedCrossRefGoogle Scholar
  120. 120.
    Garcia JV, Miller AD. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991; 350:508–511.PubMedCrossRefGoogle Scholar
  121. 121.
    Schwartz O, Marechal V, Le Gall S et al. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996; 2:338–342.PubMedCrossRefGoogle Scholar
  122. 122.
    Cohen GB, Gandhi RT, Davis DM et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-l protects HIV-infected cells from NK cells. Immunity 1999; 10:661–671.PubMedCrossRefGoogle Scholar
  123. 123.
    Le Gall S, Erdtmann L, Benichou S et al. Ncf interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998; 8:483–495.PubMedCrossRefGoogle Scholar
  124. 124.
    Swigut T, Shohdy N, Skowronski J. Mechanism for down-regulation of CD28 by Nef. EMBO J 2001; 20:1593–1604.PubMedCrossRefGoogle Scholar
  125. 125.
    Munch J, Janardhan A, Stoke N et al. T-cell receptor: CD3 down-regulation is a selected in vivo function of simian immunodeficiency virus Nef but is not sufficient for effective viral replication in rhesus macaques. J Virol 2002; 76:12360–12364.PubMedCrossRefGoogle Scholar
  126. 126.
    Munch J, Rajan D, Schindler M et al. Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol 2007; 81:13852–13864.PubMedCrossRefGoogle Scholar
  127. 127.
    Schaefer TM, Bell I, Fallert BA et al. The T-cell receptor zeta chain contains two homologous domains with which simian immunodeficiency virus Nef interacts and mediates down-modulation. J Virol 2000; 74:3273–3283.PubMedCrossRefGoogle Scholar
  128. 128.
    Swigut T, Greenberg M, Skowronski J. Cooperative interactions of simian immunodeficiency virus Nef, AP-2 and CD3-zeta mediate the selective induction of T-cell receptor-CD3 endocytosis. J Virol 2003; 77:8116–8126.PubMedCrossRefGoogle Scholar
  129. 129.
    Bell I, Ashman C, Maughan J et al. Association of simian immunodeficiency virus Nef with the T-cell receptor (TCR) zeta chain leads to TCR down-modulation. J Gen Virol 1998; 79 (Pt 11):2717–2727.PubMedGoogle Scholar
  130. 130.
    Schindler M, Munch J, Kutsch O et al. Nef-mediated suppression of T-cell activation was lost in a lentiviral lineage that gave rise to HIV-l. Cell 2006; 125:1055–1067.PubMedCrossRefGoogle Scholar
  131. 131.
    Williams M, Roeth JF, Kasper MR et al. Himian immunodeficiency virus type 1 Nef domains required for disruption of major histocompatibility complex class I trafficking are also necessary for coprecipita-tion of Nef with HLA-A2. J Virol 2005; 79:632–636.PubMedCrossRefGoogle Scholar
  132. 132.
    Ye H, Choi HJ, Poe J et al. Oligomerization is required for HIV-l Nef-induced activation of the Src family protein-tyrosine kinase, Hck. Biochemistry 2004; 43:15775–15784.PubMedCrossRefGoogle Scholar
  133. 133.
    Arold S, Hoh F, Domergue S et al. Characterization and molecular basis of the oligomeric structure of HIV-l nef protein. Protein Sci 2000; 9:1137–1148.PubMedCrossRefGoogle Scholar
  134. 134.
    Liu LX, Heveker N, Fackler OT et al. Mutation of a conserved residue (D123) required for oligomeriza-tion of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions. J Virol 2000; 74:5310–5319.PubMedCrossRefGoogle Scholar
  135. 135.
    Kienzle N, Freund J, Kalbitzer HR et al. Oligomerization of the Nef protein from human immunodeficiency virus (HIV) type 1. Eur J Biochem 1993; 214:451–457.PubMedCrossRefGoogle Scholar
  136. 136.
    Fenard D, Yonemoto W, de Noronha C et al. Nef is physically recruited into the immunological synapse and potentiates T-cell activation early after TCR engagement. J Immimol 2005; 175:6050–6057.Google Scholar
  137. 137.
    Fultz PN. Replication of an acutely lethal simian immunodeficiency virus activates and induces prolifera-tion of lymphocytes. J Virol 1991; 65:4902–4909.PubMedGoogle Scholar
  138. 138.
    Dehghani H, Brown CR, Plishka R et al. The ITAM in Nef influences acute pathogenesis of AIDS-inducing simian immunodeficiency viruses SIVsm and SIVagm without altering kinetics or extent of viremia. J Virol 2002; 76:4379–4389.PubMedCrossRefGoogle Scholar
  139. 139.
    Petit C, Buseyne F, Boccaccio C et al. Nef is required for efficient HIV-l replication in cocultures of dendritic cells and lymphocytes. Virology 2001; 286:225–236.PubMedCrossRefGoogle Scholar
  140. 140.
    Piguet V, Trono D. The Nef protein of primate lentiviruses. Rev Med Virol 1999; 9:111–120.PubMedCrossRefGoogle Scholar
  141. 141.
    Albrecht B, Collins ND, Burniston MT et al. Human T-lymphotropic virus type 1 open reading frame I p12(I) is required for efficient viral infectivity in primary lymphocytes. J Virol 2000; 74:9828–9835.PubMedCrossRefGoogle Scholar
  142. 142.
    Albrecht B, D’Souza CD, Ding W et al. Activation of nuclear factor of activated T-cells by human T-lymphotropic virus type 1 accessory protein p12(I). J Virol 2002; 76:3493–3501.PubMedCrossRefGoogle Scholar
  143. 143.
    Bindhu M, Nair A, Lairmore MD. Role of accessory proteins of HTLV-1 in viral replication, T-cell activation and cellular gene expression. Front Biosci 2004; 9:2556–2576.PubMedCrossRefGoogle Scholar
  144. 144.
    Hollsberg P, Ausubel LJ, Hafler DA. Human T-cell lymphotropic virus type I-induced T-cell activation. Resistance to TGF-beta 1-induced suppression. J Immunol 1994; 153:566–573.PubMedGoogle Scholar
  145. 145.
    Mann DL, Martin P, Hamlin-Green G et al. Virus production and spontaneous cell proliferation in HTLV-I-infected lymphocytes. Clin Immunol Immunopathol 1994; 72:312–320.PubMedCrossRefGoogle Scholar
  146. 146.
    Albrecht B, Lairmore MD. Critical role of human T-lymphotropic virus type 1 accessory proteins in viral replication and pathogenesis. Microbiol Mol Biol Rev 2002; 66:396–406.PubMedCrossRefGoogle Scholar
  147. 147.
    Ding W, Albrecht B, Kelley RE et al. Human T-cell lymphotropic virus type 1 p12(I) expression increases cytoplasmic calcium to enhance the activation of nuclear factor of activated T-cells. J Virol 2002; 76:10374–10382.PubMedCrossRefGoogle Scholar
  148. 148.
    Ding W, Kim SJ, Nair AM et al. Human T-cell lymphotropic virus type 1 p12I enhances interleukin-2 production during T-cell activation. J Virol 2003; 77:11027–11039.PubMedCrossRefGoogle Scholar
  149. 149.
    Nicot C, Mulloy JC, Ferrari MG et al. HTLV-1 p12(I) protein enhances STAT5 activation and decreases the interleukin-2 requirement for proliferation of primary human peripheral blood mononuclear cells. Blood 2001; 98:823–829.PubMedCrossRefGoogle Scholar
  150. 150.
    Johnson JM, Mulloy JC, Ciminale V et al. The MHC class I heavy chain is a common target of the small proteins encoded by the 3′ end of HTLV type 1 and HTLV type 2. AIDS Res Hum Retroviruses 2000; 16:1777–1781.PubMedCrossRefGoogle Scholar
  151. 151.
    Collins ND, Newbound GC, Albrecht B et al. Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo. Blood 1998; 91:4701–4707.PubMedGoogle Scholar
  152. 152.
    Guyot DJ, Newbound GC, Lairmore MD. Signaling via the CD2 receptor enhances HTLV-1 replication in T-lymphocytes. Virology 1997; 234:123–129.PubMedCrossRefGoogle Scholar
  153. 153.
    Von Bonin A, Ehrlich S, Fleischer B. The transmembrane region of CD2-associated signal-transducing pro-teins is crucial for the outcome of CD2-mediated T-cell activation. Immunology 1998; 93:376–382.CrossRefGoogle Scholar
  154. 154.
    Wild MK, Verhagen AM, Meuer SC et al. The receptor function of CD2 in human CD2 transgenic mice is based on highly conserved associations with signal transduction molecules. Cell Immunol 1997; 180:168–175.PubMedCrossRefGoogle Scholar
  155. 155.
    Kimata JT, Palker TJ, Ratner L. The mitogenic activity of human T-cell leukemia virus type I is T-cell associated and requires the CD2/LFA-3 activation pathway. J Virol 1993; 67:3134–3141.PubMedGoogle Scholar
  156. 156.
    Tsukahara T, Ratner L. Substitution of HIV Type 1 Nef with HTLV-1 p12. AIDS Res Hum Retroviruses 2004; 20:938–943.PubMedCrossRefGoogle Scholar
  157. 157.
    Fukumoto R, Dundr M, Nicot C et al. Inhibition of T-cell receptor signal transduction and viral expres-sion by the linker for activation of T-cells-interacting p12(I) protein of human T-cell leukemia/lymphoma virus type 1. J Virol 2007; 81:9088–9099.PubMedCrossRefGoogle Scholar
  158. 158.
    Huynh NT, Ffrench RA, Boadle RA et al. Transmembrane T-cell receptor peptides inhibit B-and natural killer-cell function. Immunology 2003; 108:458–464.PubMedCrossRefGoogle Scholar
  159. 159.
    Gerber D, Quintana FJ, Bloch I et al. D-enantiomer peptide of the TCRalpha transmembrane domain inhibits T-cell activation in vitro and in vivo. FASEB J 2005; 19:1190–1192.PubMedGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Walter M. Kim
    • 1
  • Alexander B. Sigalov
    • 1
  1. 1.Department of PathologyUniversity of Massachusetts Medical SchoolWorcesterUSA

Personalised recommendations